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(2001-2012) of 65 HSCT patients with myeloid malignan-
cies (n¼ 32), lymphoid malignancies (n¼27) or CML (n¼6)
who received DLI post-transplant to treat mixed chimerism
(MC, n¼15), minimal residual disease (MRD, n¼15) or
relapsed disease (RD, n¼35). Patients had received trans-
plants from related (n¼20) including haploidentical (n¼26),
unrelated (n¼35) or cord blood (n¼1) donors. Forty-two
patients received total body irradiation (TBI) and cyclo-
phosphamide-based conditioning while 16 received
busulfan and cyclophosphamide-based regimens. Twenty-
seven patients received conditioning with other chemo-
therapies  TBI. MC was deﬁned as evidence of recipient
cells on whole blood or bone marrow analysis using ﬂuo-
rescence in-situ hybridization (FISH) or short tandem
repeats. Nine of the 15 MC patients who received DLI did so
after the discontinuation (median of 35 days, range 1-217)
of graft versus host disease (GvHD) prophylaxis, while the 6
remaining DLI recipients had not been on prophylactic
therapy. MRD was deﬁned as the detection of a clone 
0.01% using polymerase chain reaction or FISH. Relapse was
deﬁned as any patient with a  5% blast population
detected in peripheral blood and conﬁrmed by microscopic
or ﬂow cytometric analysis. As a group, 26/65 patients are
alive after receiving DLI with a median follow-up of 24
months (range 3-102). Of patients with MC, 9/15 remained
in remission for a median of 22 months (range 3-85) with
7/15 experiencing Grade II-IV aGvHD. Of patients with
MRD, 12/15 remained in remission for a median of 77
months (range 5-102) with 5/15 experiencing grade II-IV
aGvHD. Eight of these 12 surviving patients were Phila-
delphia chromosome-positive. Of patients with RD, 5/36
remain alive with 3/5 in remission for a median of 43
months (range 4-63). 11/31 patients who expired experi-
enced Grade II-IV aGvHD. Hence, DLI may beneﬁt pediatric
myeloid and lymphoid malignancy patients post-HSCT with
MC and MRD (especially those with Philadelphia chromo-
some-positive leukemia). However, DLIs produced remis-
sion in only 3/36 patients with RD and the associated risk
of signiﬁcant GvHD likely worsens quality of remaining life
in the non-responders.167
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Interest in ex vivo hematopoietic stem and progenitor cell
(HSPC) expansion has increased in recent years due to the
growing importance of these cells in the treatment of
a variety of both malignant and non-malignant diseases. Ex
vivo expansion of cord blood-derived cells has been partic-
ularly investigated because cord is a valuable and readily
available source of HSPCs, yet contains limited numbers of
cells in each unit. Despite these efforts, most attempts to use
expanded cord blood HSPCs in the clinic have been unsuc-
cessful due to the generation of insufﬁcient numbers of cells
with the appropriate phenotype and the ability to function in
vivo.
In many ex vivo culture systems, HSPCs are cultured as
a suspension cells and cultured in the presence of various
media additives that act to enhance cell proliferation while
reducing differentiation. An often-overlooked factorinﬂuencing fate decisions is the interaction of HSPCs with
a substrate. In the natural bone marrow microenvironment,
HSPCs maintain close contact with a complex network of
stromal cells and extracellular matrix, likely indicating that
cell-cell and cell-matrix interactions play an important role
in maintaining their stem cell phenotype. With the goal of
mimicking the bone marrow stem cell niche, Arteriocyte,
Inc. has developed a 3-D nanoﬁber-based cell culture
substrate. The functionalized nanoﬁber substrate is
designed to provide topographical and substrate-immobi-
lized biochemical cues that act in synergy with media
additives to enhance HSPC proliferation while minimizing
differentiation.
Here, we present our recent work towards developing
a closed, nanoﬁber-based platform for large-scale clinical
expansions of cord blood-derived CD34+ cells. We demon-
strate that our nanoﬁber substrate expands CD34+ cells from
cord an average of more than 150-fold in 10 day culture,
which is at least 2-fold higher than that obtained in standard
tissue culture plates. Additionally, we show an approxi-
mately 1.5-fold higher proliferation of colony forming cells
and a signiﬁcantly higher engraftment rate in NSG mice for
nanoﬁber-expanded cells compared to cells cultured in
tissue culture plates. Furthermore, we demonstrate that our
nanoﬁber scaffold maintains its HSPC growth promoting
characteristics after processing into a closed culture system
and offers signiﬁcant advantages over other culture plat-
forms typically used for HSPC expansions in the clinic
(culture bags and T-ﬂasks). Our data indicates that nanoﬁber
technology provides a robust ex vivo expansion of cord blood
HSPCs and, with further development, offers great potential
for clinical applications requiring large numbers of func-
tional cells.168
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Natural killer (NK) cells are a promising tool for cancer
therapy due to their ability to detect and eliminate cancer
cells. Using NK cells for therapeutic cell transfer in the
clinic requires high numbers of these cells. Therefore
a method for automated expansion of human NK cells is
developed.
Automation of NK cell expansion was done by use of the
CliniMACS Prodigy instrument, a novel technology for cell
processing in a clinical environment. Automated Ficoll
density gradient centrifugation was performed to remove
erythrocytes and granulocytes from buffy coat samples of
healthy donors and to obtain peripheral blood mononuclear
cells (PBMC). This automated method yielded a suitable
number of PBMC and a better depletion of granulocytes
compared to the manual PBMC preparation. PBMC were
cultivated with IL-2 and OKT-3 leading to an expansion of NK
cells, but also of NK like Tcells and Tcells. NK cell numbers up
to 5,1x108were reached with expansion factors of 54-208-
fold after three weeks. NK cell purities of 5-52% were
obtained.
Pure NK preparations are preferred with regard to
analysis of clinical outcome and to reduce the risk of graft
versus host disease possibly caused by contaminating T
cells.
